Central African Republic vs Rwanda: Average cost of drugs for extensively drug-resistant tuberculosis
Central African Republic
1,500 constant 2022 US$
in 2024
Rwanda
1,483 constant 2022 US$
in 2024
Central African Republic rank
33rd
Rwanda rank
35th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Central African Republic
- Rwanda
How they compare
Central African Republic currently reports 1,500 constant 2022 US$ against 1,483 constant 2022 US$ in Rwanda, a difference of 17 constant 2022 US$.
The two have swapped places 1 time across 6 shared years of data; in 2017 it was Rwanda ahead.
Central African Republic ranks 33rd and Rwanda ranks 35th of 56 countries.
Rwanda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Central African Republic | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,000 constant 2022 US$ | 6,234 constant 2022 US$ | 4,234 constant 2022 US$ | Rwanda |
| 2020s | 1,500 constant 2022 US$ | 2,766 constant 2022 US$ | 1,266 constant 2022 US$ | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Central African Republic or Rwanda?
- Central African Republic, at 1,500 constant 2022 US$ against 1,483 constant 2022 US$ in Rwanda as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Central African Republic and Rwanda?
- 17 constant 2022 US$, with Central African Republic ahead.
- How many years of comparable data are there for Central African Republic and Rwanda?
- 6 years are reported by both, from 2017 to 2024.
- How do Central African Republic and Rwanda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Central African Republic ranks 33rd and Rwanda ranks 35th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.